Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03737123 · ClinicalTrials.gov registry record · Phase 2
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
A Phase 2 study, sponsored by Nabil Adra.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03737123 is a Phase 2 study that was terminated before completion, run by Nabil Adra. The registered enrollment target is 6 participants.
The verdict
NCT03737123, a Phase 2 study, was terminated before completion, sponsored by Nabil Adra.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single arm phase II study assessing the activity of atezolizumab in combination with carboplatin + gemcitabine or docetaxel compared to historical controls of chemotherapy only in metastatic or recurrent urothelial carcinoma subjects. Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Atezolizumab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2022-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03737123
The ClinicalTrials.gov registry entry for NCT03737123 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabil Adra, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT03737123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03737123 about?
NCT03737123 is a clinical study titled "Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma". This is a single arm phase II study assessing the activity of atezolizumab in combination with carboplatin + gemcitabine or docetaxel compared to historical controls of chemotherapy only in metastatic or recurrent urothelial carcinoma subjects. Subjects that received a PD 1 or PD-L1 inhibitor with n...
What is the current status of trial NCT03737123?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-12-19. Estimated completion is 2022-05-18.
What interventions are being tested in trial NCT03737123?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Atezolizumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03737123?
This trial is sponsored by Nabil Adra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.